Tag: THERADIAG
THERADIAG: ANNOUNCEMENT OF THE FINAL RESULTS OF BIOSYNEX’S OPA ON THERADIAG SHARES – 02/01/2023 at 18:00
Croissy-Beaubourg, February 1, 2023, 6:00 p.m. CET – The Autorité des marchés financiers (AMF) published, on February 1, 2023, a notice of the final results of the reopened public takeover…
Theradiag: premium issue
Through Claude Leguilloux Published on 01/17/2023 at 09:54 Theradiag a announced the success of the takeover bid initiated by Biosynex, targeting the shares of…
Success of the takeover bid initiated by BIOSYNEX, targeting THERADIAG shares – 01/16/2023 at 6:00 p.m.
REOPENING OF THE OFFER FOR A MINIMUM DURATION OF 10 TRADING DAYS Croissy-Beaubourg, January 16, 2023, 6:00 p.m. CET – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in…
Theradiag: Unsurprising 2022 revenue
Read also (CercleFinance.com) – The Theradiag share rose slightly by 0.7% on Monday on the Paris Stock Exchange, investors being reassured by the unsurprising activity figures published in the morning…
Biosynex: successful takeover bid for Theradiag
(CercleFinance.com) – Euronext Paris informed the AMF that on January 12, the latest date set for the filing of orders submitted to the takeover bid initiated by Biosynex for Theradiag…
Theradiag: growth of nearly 10% in 2022 – 01/16/2023 at 08:00
(CercleFinance.com) – Theradiag posted revenue of €12.2 million for 2022, an increase of 9.7% in line with its business plan, with an increased share achieved abroad (55% compared to 52%…
Theradiag: 2022 turnover without surprise
(CercleFinance.com) – The Theradiag share rose slightly by 0.7% on the Paris Stock Exchange on Monday, investors being reassured by the unsurprising activity figures published in the morning by the…
Theradiag: 2022 revenue up 9.7% – 01/16/2023 at 8:49 am
(AOF) – Theradiag reported annual revenue for 2022 of 12.2 million euros, up 9.7%. The company specializing in in vitro diagnostics generated 55% of its turnover abroad, compared to 52%…
THERADIAG: 2022 annual revenue of €12.2 million, up 9.7% – 01/16/2023 at 07:30
• Solid growth of +10.1% in Theranostics and +9.2% in IVD • Good export performance (outside the United States) materialized by an increase of +23.3% • Cash level as of…
Theradiag press release in response to the takeover bid for Theradiag shares initiated by Biosynex – 2022-11-02 at 6:00 p.m.
Theradiag press release in response to the public takeover bid for Theradiag shares initiated by Biosynex This press release has been prepared and is distributed pursuant to the provisions of…
Theradiag appoints an independent expert to examine Biosynex’s offer
By Alexandra Saintpierre Published on 03/10/2022 at 06:53 Photo credit © Reuters (Boursier.com)…
Biosynex: Theradiag appoints an independent expert within the framework of the takeover bid – 09/30/2022 at 18:19
(AOF) – Theradiag has announced the appointment of the firm Crowe HAF by the company’s board of directors as an independent expert within the framework of the proposed voluntary takeover…